NCT07043608 2025-07-02
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
Clinical Trials
23 trialsNCT03336983 2024-08-01
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT03408652 2021-10-22
MOSCAR
Centre Leon Berard
Phase 3 Terminated
NCT00058188 2020-12-08
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Northwestern University
Phase 3 Terminated
NCT00079001 2020-05-12
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00226954 2020-03-18
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00582556 2019-11-26
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Phase 2 Completed
NCT00582790 2019-11-25
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Phase 2 Terminated
NCT01205646 2019-04-12
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00869206 2018-11-07
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00193856 2017-10-12
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
Trans Tasman Radiation Oncology Group
Phase 3 Completed
NCT00081159 2016-11-10
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00685646 2015-10-16
ZAPCA
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 3 Completed
NCT01062503 2015-04-27
SubDueP
University Health Network, Toronto
Completed
NCT00151073 2015-01-22
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00181584 2013-07-11
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00004928 2013-06-19
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00490698 2013-03-18
Zoledronate With Atorvastatin in Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00294437 2012-05-01
ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
Central European Cooperative Oncology Group
Phase 3 Terminated
NCT00264420 2010-12-21
Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation
The Cleveland Clinic
Phase 1 Completed
NCT00181558 2010-05-10
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
Massachusetts General Hospital
Phase 2 Completed
NCT00415779 2010-02-24
ZANTE
National Cancer Institute, Naples
Phase 1 Completed
NCT00520052 2007-08-23
Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer
Wirral University Teaching Hospital NHS Trust
Phase NA Completed